Why did MSB fall 11.1% on 19 Oct 2026?
Mesoblast · Pharmaceuticals, Biotechnology & Life Sciences
$10,000 in MSB shares fell to $8,894 that day. It was down as much as 11.8% during the day: about 5 times a usual day's move for MSB, with twice the usual shares traded.
Mesoblast fell sharply after releasing quarterly results showing Ryoncil revenue growth that disappointed investors relative to expectations, triggering a 'sell the news' reaction despite headline growth figures.
$10,000 in ISO, the ETF that holds the most MSB, lost ▼ $9 that day. In IOZ it was a loss of $1. 17 ETFs hold MSB ›
An ETF is one investment, bought on the stock exchange, that holds many companies at once.
The news
10 of the 10 articles we read name Mesoblast. Headlines link to the publisher.
- Which Shares Led the ASX 200 on a Volatile Wednesday, Including Mesoblast (ASX:MSB)?
Kalkine Media · 22 Oct 2026
- Mesoblast Limited (ASX:MSB): 2026 Business Developments and Financial Performance
Kalkine · 21 Oct 2026
The other 8 articles ›
- Which Way Next for Mesoblast (ASX:MSB) After Ryoncil Update?
Kalkine Media · 21 Oct 2026
- Mesoblast (ASX:MSB) Slides Despite Strong Ryoncil Growth: What Disappointed Investors?
Kalkine Media · 21 Oct 2026
- ChartWatch ASX Scans: Artrya, Ansell, Bluescope Steel, Challenger, Deep Yellow, Elevra Lithium, Mesoblast, SKS Technologies
Market Index · 20 Oct 2026
- Buy, hold, sell: Mesoblast, PLS, and SEEK shares
The Motley Fool Australia · 19 Oct 2026
- Mesoblast Limited (ASX:MSB): Ryoncil Revenue, FY26 Results and Cell Therapy Pipeline
Kalkine · 19 Oct 2026
- Mesoblast Limited (ASX:MSB): Ryoncil Revenue and Operating Cash Trends in Focus
Kalkine · 19 Oct 2026
- Will Mesoblast (ASX:MSB) sustain its Ryoncil sales momentum?
Kalkine Media · 19 Oct 2026
- Why Did Mesoblast (ASX:MSB) Fall Despite Strong Ryoncil Growth?
Kalkine Media · 18 Oct 2026
How the model got there ›
Multiple news headlines published around the detection date explicitly ask 'Why Did Mesoblast Fall Despite Strong Ryoncil Growth?' and 'What Disappointed Investors?', indicating a results release where headline revenue growth was present but fell short of market expectations. The same-industry peers' median move was only -1.96% across 45 peers, and the ASX Health sector index (^AXHJ) was up +4.21%, ruling out sector_flow or broad industry pressure as the cause — this is clearly stock-specific. The -11.06% close on 1.5x normal volume is consistent with a disappointing financial update rather than a routine market move, and no ASX announcement was captured likely due to the 18-hour window cutoff, with the results appearing to have landed just outside it.
Markets that moved with it · 1
Markets that tend to move with this stock, on the same day or the day before.
- ASX 200 Health CareIts sector · same dayother way+0.04%
MSB before and after
Mesoblast: price and every explained moveWhat $10,000 in each ETF lost that day
$77 of every $10,000 in ISO was Mesoblast; it fell 11.1%, so $10,000 in ISO lost $9.
- ISO iShares S&P/ASX Small Ordinaries ETF$77 of every $10,000 was Mesoblast▼ $9
- SSO STATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$76 of every $10,000 was Mesoblast▼ $8
- FAIR BetaShares Australian Sustainability Leaders ETF$49 of every $10,000 was Mesoblast▼ $5
- VSO Vanguard MSCI Australian Small Companies Index ETF$31 of every $10,000 was Mesoblast▼ $3
- OZXX Global X Australia ex Financials & Resources ETF$30 of every $10,000 was Mesoblast▼ $3
- IOZ iShares Core S&P/ASX 200 ETF$8 of every $10,000 was Mesoblast · a widely held fund▼ $1
- A200 BetaShares Australia 200 ETF$7 of every $10,000 was Mesoblast · a widely held fund▼ $1
- VAS Vanguard Australian Shares Index ETF$7 of every $10,000 was Mesoblast · a widely held fund▼ $1
9 more ETFs ›
- EX20 BetaShares Australian Ex-20 Portfolio Diversifier ETF$21 of every $10,000 was Mesoblast▼ $2
- GEAR BetaShares Geared Australian Equities Complex ETF$17 of every $10,000 was Mesoblast▼ $2
- VETH Vanguard Ethically Conscious Australian Shares ETF$9 of every $10,000 was Mesoblast▼ $1
- STW STATE STREET SPDR S&P/ASX 200 ETF$8 of every $10,000 was Mesoblast▼ $1
- AYLD Global X S&P/ASX 200 Covered Call Complex ETF$8 of every $10,000 was Mesoblast▼ $1
- AUST BetaShares Managed Risk Australian Shares Complex ETF$8 of every $10,000 was Mesoblast▼ $1
- A300 Global X Australia 300 ETF$7 of every $10,000 was Mesoblast▼ $1
- ROYL BetaShares Global Royalties ETF$7 of every $10,000 was Mesoblast▼ $1
- VGE Vanguard FTSE Emerging Markets Shares ETFunder $1 of every $10,000 was Mesoblastunder $1